Xiu‐Da Shen, Bibo Ke, Yuan Zhai, Feng Gao, Dean Anselmo, Charles R. Lassman, Ronald W. Busuttil, Jerzy W. Kupiec‐Weglinski – 30 December 2003 – Ischemia/reperfusion (I/R) injury remains an important problem in clinical organ transplantation. There is growing evidence that T lymphocytes, and activated CD4+ T cells in particular, play a key role in hepatic I/R injury. This study analyzes the role of signal transducer and activator of transcription 4 (Stat4) and Stat6 signaling in liver I/R injury.

Lia Bellis, Annalisa Berzigotti, Juan G. Abraldes, Eduardo Moitinho, Juan C. García‐Pagán, Jaime Bosch, Juan Rodés – 30 December 2003 – Postprandial hyperemia is associated with a significant increase in portal pressure in cirrhosis, which may contribute to progressive dilation and rupture of gastroesophageal varices. In cirrhosis, an insufficient hepatic production of nitric oxide (NO) may impair the expected hepatic vasodilatory response to increased blood flow, further exaggerating the postprandial increase in portal pressure.

Paul J. Gow, Siddharth Sood, Peter W. Angus – 30 December 2003

Ivan Borbath, Yves Horsmans – 30 December 2003

Ming Qiao, Kazumoto Murata, Anthony R. Davis, Sook‐Hyang Jeong, T. Jake Liang – 30 December 2003 – We have previously described the generation of hepatitis C virus–like particles (HCV‐LPs) in insect cells and shown that immunization with HCV‐LPs elicited both humoral and cellular immune responses in mice. To further characterize the HCV‐LPs as a vaccine candidate, we evaluated the effects of adjuvant AS01B (monophosphoryl lipid A [MPL] and QS21), CpG 10105, and the combination of the 2 adjuvants on the immunogenicity of HCV‐LPs in AAD mice (transgenic for HLA‐A2.1).

Francesco Negro – 30 December 2003

Patrick Marcellin, Tarik Asselah, Nathalie Boyer – 30 December 2003 – The progression of fibrosis in chronic hepatitis C determines the ultimate prognosis and thus the need and urgency of therapy. Fibrogenesis is a complex dynamic process, which is mediated by necroinflammation and activation of stellate cells. The liver biopsy remains the gold standard to assess fibrosis. Scoring systems allow a semiquantitative assessment and are useful for cross‐sectional and cohort studies and in treatment trials. The rate at which fibrosis progresses varies markedly between patients.

Mike A. Leonis, Kenya Toney‐Earley, Sandra J. F. Degen, Susan E. Waltz – 30 December 2003 – The targeted deletion of the cytoplasmic domain of the Ron receptor tyrosine kinase (TK) in mice leads to exaggerated responses to injury in several murine models of inflammation as well as increased lethality in response to endotoxin (lipopolysaccharide [LPS]). Using a well‐characterized model of LPS‐induced acute liver failure (ALF) in galactosamine (GalN)‐sensitized mice, we show that Ron TK−/− mice display marked protection compared with control Ron TK+/+ mice.

Michael W. Fried – 30 December 2003 – Interferon and ribavirin combination therapy for chronic hepatitis C produces a number of well‐described side effects that are dominated by fatigue, influenza‐like symptoms, hematologic abnormalities, and neuropsychiatric symptoms. Combination therapy with pegylated interferons (peginterferon alfa‐2a and alfa‐2b) yields an adverse event profile similar to standard interferon, although the frequency of certain adverse events may vary by preparation.

Robert J. Fontana, Anna S. F. Lok – 30 December 2003 – Hepatic fibrosis is the main determinant of clinical outcomes of chronic hepatitis C. Liver histology is frequently considered the gold standard for assessing hepatic fibrosis. However, liver biopsy is associated with sampling error, interobserver variability, and potential complications. Thus, there is a need for simple, inexpensive, and reliable noninvasive means to assess disease severity in patients with chronic hepatitis C. Clinical examination is unreliable in differentiating different stages of compensated liver disease.